There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) 
INTRODUCTION
The emergence of direct-acting antiviral agents (DAAs) has dramatically transformed the chronic hepatitis C (HCV) treatment landscape. Compared to the historic regimen of pegylated interferon (PEG-IFN) and ribavirin (RBV), DAAs exhibit both increased tolerability and efficacy. Anticipated frequencies of sustained virologic response (SVR12), defined as an undetectable HCV RNA viral load at 12 weeks after completion of therapy, are now[90% for many DAA-containing therapies [1] . Achievement of SVR is associated with numerous health benefits including regression of fibrosis, a substantial reduction in the risk of hepatocellular carcinoma, and a 90% reduction in liver-related mortality [1] . Despite these benefits, only about 5% of the estimated 2.2-3.2 million Americans infected with chronic HCV (though nearly half are unaware of their diagnosis) receive treatment [1, 2] . While current therapies are highly efficacious and effective, many are extremely patient-specific and treatment selection is driven by viral genotype, presence of cirrhosis, use of concomitant medications, and many other considerations. They are also costly and may not be accessible to all patients. Therefore, while the approval of the DAAs is a welcomed advancement compared to therapies containing PEG-IFN and RBV, there are severable desirable traits of an ''ideal'' HCV therapy that have yet to be possessed by a single regimen. Emergence of this highly-desirable therapy would mean a step closer to HCV control and elimination in the United States. The purpose of this review is to (1) identify the characteristics of an ideal HCV treatment regimen, (2) describe desirable features of existing regimens, (3) summarize limitations of existing regimens, and (4) present promising emerging therapies. This review will discuss ledipasvir/sofosbuvir (LDV/ SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD), simeprevir/sofosbuvir (SIM/SOF), daclatasvir/sofosbuvir (DAC/SOF), and grazoprevir/elbasvir (GZR/EBR). Given its similarity to PrOD, PrO will not be discussed [3] .
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
EFFICACIOUS AND EFFECTIVE
While intuitive, an ideal HCV regimen should be one that demonstrates high efficacy and effectiveness. Cure of infection is defined as achievement of sustained virologic response (SVR), or undetectable HCV RNA viral load, several weeks post-therapy completion.
Historically, cure was assessed at 6 months (SVR24) after completion of up to 48 weeks of therapy. Considering that assessment at 12 weeks post-therapy completion has shown to be equally relevant [4] , and that many contemporary treatment regimens are only However, probability of cure remains highly patient-and regimen-specific (e.g., presence of the Q80K mutation in GT1a-infected, treatment-experienced, cirrhotic patients is associated with failure to SIM/SOF) [7, 8] . For DAC/SOF and LDV/SOF, the most commonly reported adverse events were minor, including fatigue and headache [9, 10] .
For SIM/SOF, a unique adverse effect is a variety of dermatologic manifestations including rash and pruritus. This typically occurs within 4 weeks of therapy initiation and may be due to certain drug chemical properties (e.g., SIM has a sulfa-like moiety) and/or photosensitivity potential [7] . PrOD, though generally well-tolerated in clinical studies, may cause serious hepatic injury. Patients with advanced liver disease appear to be particularly susceptible, as described in a recently issued FDA warning [3, 11] . Additionally, PrOD is often co-administered with RBV, which can cause hemolytic anemia. Considering the toxicity potential of many currently available HCV therapies, an ideal treatment regimen would have a favorable toxicity profile with minimal risk of serious adverse events.
Devoid of Drug-Drug Interactions
While adverse effects of each regimen should be considered, it is also important to assess the safety of anti-HCV agents when given concomitantly with other medications. Drug-drug interactions (DDIs) are of substantial concern in the HCV-infected population, given that treatment regimens consist of multiple treatment medications for patients that frequently have medically managed comorbidities [12] . Many interactions involve the cytochrome (CYP) P450 isoenzyme system, including CYP3A4, which metabolizes DAAs and several other classes of medications [7] . Among the HCV regimens, SIM is an inhibitor of intestinal CYP3A4 and the ritonavir component of PrOD is involved in the hepatic inhibition of CYP3A4 as well as several other CYP isoenzymes [7, 11] .
GZR is a weak inhibitor of CYP3A4 and may be implicated in fewer interactions [13] . LDV and EBR are inhibitors of p-glycoprotein (PGP) and breast cancer receptor protein (BCRP) [9, 13] .
DAC is an inhibitor of PGP and organic anion transporter protein (OATP) 1B1 [10] .
DDIs involving each of the HCV regimens and common classes of medications are displayed in Table 2 HCV co-infected patients using efavirenz or protease-inhibitor containing regimens [9] .
However, the degree of enhanced exposure Today, several HCV treatments possess select attributes of an ideal regimen. LDV/SOF and GZR/EBR offer the convenience of single, fixed-dose combination tablet regimens, substantially decreasing treatment pill burden [9, 13] . Dosing frequency has also improved given that the majority of HCV treatment regimens for GT1 infection are dosed once daily [7, 9, 10, 13] . The exception to this is the dasabuvir component of the PrOD regimen, which is dosed twice daily [11] . While the remaining regimens may be administered once daily, some may require concomitant use of twice daily RBV, particularly in patients with cirrhosis and who have previously failed therapy [7, [9] [10] [11] 13] . 
ACCESSIBLE AND AFFORDABLE
An ideal HCV regimen will be one that is affordable and relatively easy to obtain for patients from all socioeconomic backgrounds.
Many of these therapies are offered through patient assistance programs to increase accessibility and affordability for qualifying individuals. However, many patients with HCV infection face numerous barriers hampering access to optimal therapy [26]. In the US, barriers include high treatment costs, lack of third party payer coverage or coverage contingencies, requirement for prior authorization approval, and therapy restriction to only patients with severe infection. These limitations and restrictions greatly complicate patient access to appropriate HCV treatment. This is particularly concerning given the evidence that delays in therapy are associated with an increased risk of adverse HCV-associated outcomes [1] . The most widely discussed barrier is the high treatment cost, which may not be affordable out-of-pocket for the vast number of HCV-infected patients that are uninsured or underinsured [13] . While the true cost of these medications to third party payers is largely unknown due to proprietary contract pricing, average wholesale pricing of many 12-week courses of DAA treatments are in excess of US$90,000 for the medication alone (i.e.
monitoring and clinic visit costs are not included in this price) [10] . Currently, the least expensive regimen is the newly-approved GZR/EBR, costing approximately US$55,000 [11] . For those with prescription insurance, high copayments or deductibles may still exist. Additionally, while manufacturer-based patient assistance programs exist for the DAAs, some are associated with income restrictions or manufacturer specific guidelines for treatment [27] . If a patient does have prescription insurance, various restrictions to DAA coverage may apply.
One restriction is prior authorization (PA), whereby clinicians must provide written justification to a third party payer as to why the medication is necessary for the patient.
Additional patient requirements may include urine toxicology panels, urine pregnancy tests, or a consent form by which the patient pledges adherence to medication therapy and follow-up appointments. This added layer of approvals imposed by some third-party payers requires dedicated resources that may not be taken into account by many cost-effectiveness models [28] .
Restrictions may also apply for severity of infection, which is commonly characterized by the METAVIR score that assesses liver necroinflammation and fibrosis. One study indicated that among the 42 states with known Medicaid restriction criteria for SOF, 74% limit treatment to patients with the highest METAVIR scores of F3 or F4 [29] . There is limited evidence to support some of the aforementioned requirements [1] . However, with more widespread use of DAA-containing regimens, there may be more evidence in the future to support or refute HCV ''stewardship,'' such as rationing new agents for difficult patients and inexpensive agents for less complex patients. Notably, many of the logistical issues described above are unique to the US and may not be germane to other geographic locales, or in the future with movement towards universal healthcare coverage. As more HCV-infected patients obtain access to treatment, infection rates by transmission may decline and subsequently decrease the overall societal and financial burden of HCV. An ideal regimen would be affordable and accessible for all patients seeking treatment.
HIGH BARRIER TO RESISTANCE
High efficacy demonstrated by several HCV regimens means treatment success for many patients. However, in the event of relapse or treatment failure, an ideal therapy would exhibit a high barrier to resistance with little potential for cross-resistance with other agents. Some regimens are affected by baseline NS5A
mutations. Among GT1A-infected patients receiving 12 weeks of GZR/EBR, SVR was lower among patients with at least one baseline NS5A
resistance-associated polymorphism at amino acid positions 28, 30, 31 or 93 [3, 9] . Thus, patients with GT1A infection initiating GZR/ EBR need to undergo NS5A testing. The presence of any of these four polymorphisms extends therapy from 12 to 16 weeks and requires the addition of ribavirin [3, 9] . As the use of NS5A inhibitors becomes more ubiquitous and the issues of cross-resistance and persistence of NS5A and NS3 mutations are better understood, the impact of this test may become applicable to other treatment regimens.
Findings may steer certain patient populations from using these therapies. Cross-resistance exists for some available agents including the protease inhibitors, SIM and paritaprevir [7, 11] . SOF is advantageous in that it exhibits a high barrier to resistance and, when used in combination with other DAA agents, may still be used successfully to overcome the presence of baseline antiviral resistance-associated variants (RAV) [9, 16] . LDV/SOF may offer a promising treatment option for patients who have failed a RBV-containing regimen or SIM/ SOF (though addition of RBV to LDV/SOF is recommended for the latter); however, data are limited [9] . PEG-IFN, though no longer a component of most preferred regimens, maintains activity in the setting of RAVs and therefore remains a viable adjunctive option for many treatment-experienced patients [1] . In addition to regimens offering broad-spectrum genotypic activity, shorter treatment durations are also being pursued.
FUTURE DIRECTIONS
Several 4-and 6-week combination therapy regimens (2-3 agents) are being explored in phase II studies that will hopefully add additional highly efficacious, multigenotypic therapies to the growing HCV treatment armamentarium [30] . Though further beyond the horizon, emergence of generic treatment options will likely alter the treatment landscape once again. A series of questions will arise pertaining to cost-effectiveness of branded single-tablet regimens versus less expensive multiple-tablet regimens and the impact on regimen adherence and ultimate treatment success.
CONCLUSIONS
As the treatment landscape for chronic HCV infection continues to rapidly evolve, the characteristics associated with an ideal regimen remain constant. An ideal regimen is one that is efficacious in a variety of populations, convenient, safe, accessible/ affordable, and has a high barrier to resistance. Although significant progress has been made, no commercially available regimen fully achieves each of these desirable characteristics. It is imperative for continued research and development to achieve these goals to produce dramatic reductions in HCV infection burden globally. 
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